RBSHREBUS HLDGS INC.

About REBUS HLDGS INC. (RBSH)

REBUS HLDGS INC. (RBSH) is a Biotechnology company headquartered in Westlake Village, CA, United States whose shares trade over-the-counter on the Expert Market tier.

Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company's drug candidates within a tumor. Inspyr's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.

RBSH key facts

Ticker symbol

RBSH

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Westlake Village, CA, United States

Country of incorporation

US

Year of incorporation

2003

Employees

4

Estimated market cap

$3.2K (as of Apr 15, 2025)

Shares outstanding

32,132,907

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

REBUS HLDGS INC. leadership

• Robert A. Scherne — Accountant
• Dennis Gluck — Other

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with R